Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting
Read the full statement from Zevra Therapeutics here:
Here is a summary of the article:
Clinical Benefits: The data from the Expanded Access Program showed a consistent safety profile and a clinically meaningful slowing of disease progression in adults with NPC.
Regulatory Progress: The FDA has accepted the resubmission of the NDA for Arimoclomol with a PDUFA date set for September 21, 20242.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Check out upcoming events
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.